SCHEMBL2211269

SCHEMBL2211269

c1ccc(-c2nnc(Nc3ccc(Oc4ccnc5cc(-c6cn[nH]c6)ccc45)cc3)c3ccccc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 2/20 0.54
FGFR2 P21802 2/20 0.48
AURKA O14965 3/20 0.47
AURKB Q96GD4 2/20 0.47
TPX2 Q9ULW0 2/20 0.47
MAPT P10636 6/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 2/20 0.42
NPSR1 Q6W5P4 1/20 0.41
POLB P06746 1/20 0.41
ENPP3 O14638 3/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.40
KDR P35968 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211081 0.83 FGFR2 (0.50) ALKFGFR2AURKAAURKBTPX2
SCHEMBL2210992 0.83 FGFR2 (0.58) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2210553 0.81 FGFR2 (0.48) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2209486 0.81 FGFR2 (0.48) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2207029 0.80 FGFR2 (0.72) FGFR2MAPTLMNAKDR
SCHEMBL15663455 0.79 MAPT (0.46) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2209361 0.79 FGFR2 (0.55) FGFR2AURKAAURKBTPX2MAPT
SCHEMBL2213005 0.79 IKBKB (0.46) ALKFGFR2AURKAAURKBTPX2
SCHEMBL15663382 0.79 MAPT (0.54) FGFR2MAPTLMNAENPP3TP53
SCHEMBL2210774 0.79 AURKA (0.49) FGFR2AURKAAURKBTPX2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 ALK 283/4885FGFR2 334/4885AURKA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.